FMBA Institute has submitted documents for registration of the drug against coronavirus “MIR 19”

The Institute of Immunology of the Federal Biomedical Agency has submitted documents for registration of the drug from COVID-19 “MIR 19”. This was reported by RIA Novosti with reference to the data of the register of medicines.

“Information related to the implementation of state registration. Trade name: “MIR 19”, – the document says.

Earlier, the head of the FMBA, Veronika Skvortsova, said that the agency would submit documents for registration of the drug against coronavirus “MIR 19” after the end of the second phase of clinical trials.

The first phase of human clinical trials was completed in March this year and showed the safety of the drug “MIR 19”.